People completing a course of obesity medication, or completing a weight-management programme, need better support to help ...

UBS has lowered its rating on Novo Nordisk (NYSE:NVO) from 'buy' to 'neutral', slashing the price target to DKK340 from ...

Novo Nordisk, the Danish maker of the wildly popular Ozempic and Wegovy drugs used for weight loss, was downgraded due to ...

UBS downgraded its rating of Novo to "neutral" from "buy" and lowered its 12-month price target to 340 Danish krone from 600 Danish krone. Copenhagen-listed shares in Novo, which have slumped by more ...

Demand for weight-loss and diabetes drugs seen global surge, CEO says move will come once patents begin to expire next year ...

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some ...

Drugmaker Sandoz could offer unbranded weight-loss drugs at an up to 70 per cent discount to the branded versions in Canada ...

Swiss generic drug manufacturer Sandoz plans to launch unbranded weight-loss drugs in Canada at discounts of up to 70% compared to branded versions once patents begin to expire next year, CEO Richard ...

Pancreatitis, vision loss ... the risks of drugs such as Ozempic can sound scary. But what does the evidence show?

Wilson previously called political opponent Zoe Daniel “divisive” for signing an open letter that labelled Israel an apartheid regime. In the world according to Timmy, using the term to describe ...

Eli Lilly ( LLY 0.73%) has been a terrific investment in recent years. Thanks to significant clinical progress and outstanding financial results, the company has become the largest healthcare player ...

Consensus analyst estimates for Novo Nordisk (NVO) earnings per share and revenue land at $0.92 and $11.9 billion, ...